secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOCEPT INC (—)
CIK:        0001044378
Form:       8-K
Filed at:   2023-06-21T23:59:59+00:00
Accession:  0001193125-23-171148
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Biocept appoints Antonino Morales as President and CEO; Riccitelli resigns
--------------------------------------------------------------------------

- Samuel D. Riccitelli resigned as Interim President and CEO and from Board, effective June 16, 2023.
- Antonino Morales appointed President and CEO; continues as CFO and Board member.
- Morales' base salary increased from $400K to $470K; target bonus raised from 40% to 50%.
- Robert Walsh promoted to VP, Controller and principal accounting officer.
- Walsh, a CPA, joined Biocept in May 2022; previously at PwC and CFGI.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1044378/000119312523171148/0001193125-23-171148-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1044378/000119312523171148/d524228d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-171148

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer